Phio Pharmaceuticals

Phio präsentiert PH-762-Daten auf der AACR
investors.phiopharma.com/news-releases/...1-targeting-intasyl

Vorbörslich +10%

https://www.ariva.de/news/...-2020-year-end-financial-results-9303874

und da gabs ja schon ein split.oh man was für flachzangen.

PHIO PHARMACEUTICALS PRESENTS POSITIVE IN VIVO DATA SHOWING STRONG TUMOR CONTROL FOR THE INTRATUMORAL DELIVERY OF INTASYL RNAI TARGETING PD-1
Apr 10, 2021
Data presented at the AACR Annual Meeting 2021
investors.phiopharma.com/news-releases/...data-showing-strong

Wenig Volumen.. Aber vielleicht doch der Kickstarter für eine Trendwende !?

Deswegen ?
investors.phiopharma.com/news-releases/...presentations-asgct

Abstract 431; www.cell.com/action/showPdf?pii=S1525-0016%2821%2900206-9

investors.phiopharma.com/news-releases/...-data-asgct-showing
PHIO PHARMACEUTICALS PRESENTS POSITIVE IN VIVO DATA AT ASGCT SHOWING PH-762 SIGNIFICANTLY ENHANCED ANTITUMOR EFFICACY OF HER2-TARGETED CAR-T CELLS
May 11, 2021

PHIO PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
May 13, 2021
investors.phiopharma.com/news-releases/...rter-2021-financial

investors.phiopharma.com/news-releases/...ta-2021-asco-annual
NEWS RELEASE DETAILS
PHIO PHARMACEUTICALS PRESENTS NEW IN VIVO DATA AT THE 2021 ASCO ANNUAL MEETING SHOWING DUAL-TARGETING INTASYL OFFERS INCREASED EFFICACY AND SAFETY POTENTIAL OVER OTHER THERAPEUTIC APPROACHES
Jun 4, 2021

investors.rxipharma.com/news-releases

Krebs-Immuntherapie mit Hilfe von mRNA-Impfstoffen! Hört sich spannend an, bei Erfolg ist der zukünftige Aktienkurs vorprogrammiert.

PHIO PHARMACEUTICALS ANNOUNCES UPCOMING DATA PRESENTATION AT THE ESMO VIRTUAL CONGRESS 2021
Aug 31, 2021
MARLBOROUGH, Mass., Aug. 31, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL TM) therapeutic platform, today announced that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held from September 16-21, 2021.

Details are as follows:
Event: ESMO Virtual Congress 2021
Title: Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors
Authors: Benjamin Cuiffo, et al.
Abstract Number: #4154
Date: September 16-21, 2021  

https://www.ariva.de/news/...icals-presents-data-at-esmo-2021-9769652

Kurs springt vorbörslich... Hoffentlich mal nachhaltig

www.nasdaq.com/market-activity/stocks/phio/real-time

https://www.ariva.de/news/...eduled-to-participate-in-the-h-c-4849344

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma
Jan 11, 2022
investors.phiopharma.com/news-releases/...-clearance-clinical
MARLBOROUGH, Mass., Jan. 11, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL TM) therapeutic platform, today announced that it has received regulatory clearance to start a clinical trial with its lead product candidate, PH-762. The Company was granted the clinical trial authorization (CTA) by the French National Agency for the Safety of Medicines and Health Products (ANSM - L'Agence nationale de sécurité du médicament et des produits de santé) to proceed with a first-in-human clinical trial for PH-762 to treat patients with melanoma at the Gustave Roussy Institute. The Company expects to dose the first patient in the first quarter of 2022.

"Receiving this clinical trial authorization is an important milestone for Phio as it is the first clinical study of a new generation of immuno-oncology therapeutics based on our INTASYL self-delivering RNAi platform," said Dr. Gerrit Dispersyn, President and CEO of Phio. "This milestone is the first of several planned for this year, as we continue to accelerate our development of our clinical and preclinical product candidates."

PH-762 activates immune cells to better recognize and kill cancer cells. It does so by reducing the expression of PD-1, a clinically validated target for immunotherapy. PD-1 is expressed by T cells and prevents them from killing other cells, including cancer cells. Therefore, reducing PD-1 expression can reduce the ability of cancer cells to evade T cell detection and killing. In preclinical studies, PH-762 has demonstrated robust and durable efficacy in various in vivo tumor models, and importantly has shown that it can elicit an abscopal effect or systemic immune response after local administration.

The Company's first clinical trial with PH-762 will be a Phase 1b study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of PH-762 in a neoadjuvant setting in subjects with advanced melanoma. There are currently no neoadjuvant treatment options approved for these patients. The study features a dose escalation of PH-762 monotherapy and is designed to allow for a data driven evaluation of the recommended Phase 2 dose..."

Da fehlte ein wichtiger Satz aus der Überschrift..;

"French regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first quarter of 2022"